PHARMA NEWS

Sustained survival benefit with tremelimumab and durvalumab as first line treatment for patients with advanced hepatocellular carcinoma: 4-year data from the phase III HIMALAYA trial

BJMO - 2023, issue Special, november 2023

T. Feys MBA, MSc

Read more

Cabozantinib plus nivolumab shows promising efficacy in metastatic non–clear-cell RCC

BJMO - 2023, issue Special, november 2023

No authors

Read more

Trastuzumab deruxtecan demonstrates promising clinical activity in patients with HER2-mutant metastatic non-small cell lung cancer

BJMO - 2023, issue Special, november 2023

No authors

Read more

Immuno Oncology Talks: shedding light on cutting edge science in the development of immunological therapies for the treatment of cancer

BJMO - 2023, issue Special, july 2023

No authors

Read more